Results 121 to 130 of about 307,945 (311)
Enzymes of the 2‐hydroxyacyl‐CoA lyase group catalyze the condensation of formyl‐CoA with aldehydes or ketones. Thus, by structural adaptation of active sites, practically any pharmaceutically and industrially important 2‐hydroxyacid could be biotechnologically synthesized. Combining crystal structure analysis, active site mutations and kinetic assays,
Michael Zahn +4 more
wiley +1 more source
Explicit construction of girth-eight QC-LDPC codes and its application in CRT method
For arbitrary code lengths of the form PL(P≥3L<sup>2</sup>/4+L-1),a new family of (4,L)-regular quasi-cyclic (QC) low-density parity-check (LDPC) codes was proposed explicitly with girth ight.Employing the new code as a component code in the ...
Guo-hua ZHANG, Rong SUN, Xin-mei WANG
doaj +2 more sources
Matrix Code Based Error Correction for LUT Based Cyclic Redundancy Check
Neepa P. Mathew, Anith Mohan
openalex +1 more source
Roos bound for skew cyclic codes in Hamming and rank metric
Gianira N. Alfarano +2 more
openalex +2 more sources
Promiscuous stimulation of HSP70 ATPase activity by parasite‐derived J‐domains
The malaria parasite Plasmodium falciparum exports three highly homologous yet functionally divergent J‐domain proteins into human erythrocytes. Here, we show that J‐domains isolated from all three proteins effectively stimulate the ATPase activity of both endogenous host and exported parasite HSP70 chaperones.
Julian Barth +6 more
wiley +1 more source
openaire +2 more sources
DNA Cyclic Codes Over The Ring $ \F_2[u,v]/\langle u^2-1,v^3-v,uv-vu \rangle$ [PDF]
Sukhamoy Pattanayak +2 more
openalex +1 more source
Accelerated Progression of Gait Impairment in Parkinson's Disease and REM Sleep Without Atonia
ABSTRACT Objective People with Parkinson's disease (PD) and rapid eye movement (REM) sleep without atonia (RSWA) often have more severe gait disturbances compared to PD without RSWA. The association between the presence and expression of RSWA and the rate of progression of gait impairment in PD is unknown.
Sommer L. Amundsen‐Huffmaster +11 more
wiley +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source

